Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.

Cancer Res · 2022 · PMC8770599 · PMID 34810199

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

of borderline significanceno p-value reported

Furthermore, the clinical benefits of PARPi therapy in HR-proficient HGSOCs (which account for about 50% of HGSOCs) are of borderline significance ( 6, 11 ).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.